Category:Peptides

From Retapedia, the free peptide encyclopedia

All peptide compounds catalogued on Retapedia, regardless of natty status.

Pages in this category

This category contains the following 21 pages.

  • 5-Amino-1MQ — Oral small-molecule NNMT inhibitor that raises NAD+ and S-adenosyl methionine to boost fat-cell energy expenditure. Studied only in rodents for fat loss; no human trials exist.
  • BPC-157 — Speeds healing of tendons, ligaments, muscles, and gut. Reduces inflammation and muscle soreness. Minimizes scar tissue formation.
  • Bremelanotide — FDA-approved (as Vyleesi) for low sexual desire in premenopausal women. Activates central melanocortin receptors to drive arousal. Shows preclinical promise for erectile dysfunction. Given by subcutaneous injection.
  • CJC-1295 — Increases growth hormone and IGF-1 for 6+ days per injection. Improves body composition, muscle recovery, and fat metabolism. Weekly dosing.
  • Delta-sleep-inducing peptide — A neuropeptide named for inducing delta EEG sleep activity in animals, though its own link to human sleep is weak and poorly characterized. Shows preclinical antiepileptic activity.
  • Epithalon — Marketed as an anti-aging peptide. In preclinical studies it boosts telomerase activity, supports the body's own melatonin production, and shows antioxidant effects. Human evidence is minimal.
  • ghk-cu — Copper-binding tripeptide that supports skin regeneration, collagen synthesis, wound healing, and hair growth, with antioxidant and anti-inflammatory activity. Used topically in cosmetics; deeper effects remain investigational.
  • Glutathione — The body's master intracellular antioxidant. Scavenges free radicals and supports liver phase-II detoxification. Regenerates vitamins C and E. Used for liver health, skin brightening, and anti-aging.
  • IGF-1 LR3 — Powerfully increases muscle growth, protein synthesis, and fat burning. Accelerates tissue repair and recovery. Risk of hypoglycemia.
  • Ipamorelin — Selectively triggers growth hormone release without raising cortisol or prolactin. Human efficacy unproven: a Phase 2 trial failed and body-composition benefits remain preclinical. Subcutaneous injection.
  • MK-677 — Oral ghrelin receptor agonist that raises growth hormone and IGF-1. Increases lean mass, bone density, and deep sleep. Causes insulin resistance and elevated blood sugar.
  • mots-c — Mitochondrial-derived peptide that activates AMPK to improve insulin sensitivity and reproduce exercise-like metabolic adaptations in preclinical models. Investigational and WADA-banned; no approved human use.
  • NAD+ — Boosts cellular energy production and DNA repair. Activates longevity enzymes. Improves metabolism and mitochondrial health. Cellular benefits proven, human longevity unproven.
  • Ozempic — Reduces appetite and slows digestion for 15-21% weight loss. Improves blood sugar control. Lowers heart attack and stroke risk by 20%.
  • RAD140 (Vosilasarm) — Increases muscle and bone mass. Weight gain up to 10% in 28 days. Risk of liver damage and testosterone suppression.
  • Retatrutide — Triple agonist that curbs appetite and raises energy expenditure for 24% weight loss. Improves blood sugar, lowers blood pressure, and normalizes liver fat. Investigational; not FDA-approved.
  • Sermorelin — Stimulates the pituitary to release growth hormone and IGF-1 under normal feedback control. FDA-approved for GH deficiency; used off-label for anti-aging via nightly injection.
  • TB-500 — Speeds wound healing, muscle and tendon recovery. Reduces inflammation, improves joint mobility, minimizes scar tissue formation.
  • Tesamorelin — Stimulates growth hormone release, lowering visceral abdominal fat and triglycerides. FDA-approved for HIV-associated lipodystrophy. Daily subcutaneous injection; fat reaccumulates when stopped.
  • Thymosin α-1 — Sharpens adaptive immunity by driving T-cell maturation and dendritic cell activity. Approved abroad as Zadaxin for chronic hepatitis B and as a vaccine adjuvant. Subcutaneous injection.
  • Tirzepatide — Dual GIP/GLP-1 agonist. Reduces appetite for up to 21% weight loss. Improves blood sugar and diabetes control. First drug approved for obstructive sleep apnea. GI side effects common.
Categories: Peptides | Bioactive molecules